Exencial Wealth Advisors LLC Has $6.45 Million Stake in Johnson & Johnson (NYSE:JNJ)

Exencial Wealth Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,573 shares of the company’s stock after buying an additional 1,000 shares during the period. Exencial Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $6,446,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the third quarter worth approximately $213,000. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after buying an additional 111,570 shares during the last quarter. ASB Consultores LLC increased its holdings in Johnson & Johnson by 5.2% in the third quarter. ASB Consultores LLC now owns 5,061 shares of the company’s stock worth $820,000 after buying an additional 248 shares during the last quarter. United Advisor Group LLC increased its holdings in Johnson & Johnson by 18.7% in the third quarter. United Advisor Group LLC now owns 5,563 shares of the company’s stock worth $902,000 after buying an additional 876 shares during the last quarter. Finally, Clarity Financial LLC boosted its position in Johnson & Johnson by 9.7% during the third quarter. Clarity Financial LLC now owns 6,371 shares of the company’s stock worth $1,032,000 after purchasing an additional 561 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Barclays upped their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Down 0.1 %

Shares of JNJ stock opened at $165.22 on Thursday. The stock has a market cap of $397.79 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a fifty day moving average price of $152.11 and a 200 day moving average price of $156.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.